url:https://finance.yahoo.com/news/vertex-vrtx-q3-earnings-key-143025319.html
title:Vertex_VRTX_Q3_Earnings_How_Key_Metrics_Compare_to_Wall_Street_Estimates
For the quarter ended September 2023, Vertex Pharmaceuticals (VRTX) reported revenue of $2.48 billion, up 6.4% over the same period last year. EPS came in at $4.08, compared to $4.01 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $2.48 billion, representing a surprise of -0.06%. The company delivered an EPS surprise of +4.08%, with the consensus EPS estimate being $3.92.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Vertex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenues- United States: $1.55 billion versus the three-analyst average estimate of $1.51 billion.
Geographic Revenues- Outside of the United States: $929.30 million compared to the $965.10 million average estimate based on three analysts.
Revenues by Product- Trikafta/Kaftrio: $2.27 billion versus the 10-analyst average estimate of $2.26 billion. The reported number represents a year-over-year change of +13.1%.
Revenues by Product- Kalydeco: $112.80 million compared to the $115.23 million average estimate based on seven analysts. The reported number represents a change of -18.9% year over year.
Revenues by Product- Orkambi: $63 million compared to the $79.78 million average estimate based on seven analysts. The reported number represents a change of -56.9% year over year.
Revenues by Product- Symdeko: $33.40 million versus $28.52 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -12.1% change.
View all Key Company Metrics for Vertex here>>>Shares of Vertex have returned +4.9% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Related Quotes